Loading clinical trials...
Loading clinical trials...
A Phase 1, Multicenter, Open-Label, Single-Arm, Multiple Dose Study to Evaluate the the Pharmacokinetics and Pharmacodynamics of Natalizumab in Pediatric Subjects With Relapsing Remitting Multiple Sclerosis (RMS)
Conditions
Interventions
Natalizumab
Locations
5
Italy
Research Site
Cefalù, Italy
Research Site
Gallarate, Italy
Research Site
Milan, Italy
Research Site
Padua, Italy
Research Site
Rome, Italy
Start Date
July 1, 2013
Primary Completion Date
September 1, 2014
Completion Date
September 1, 2014
Last Updated
June 23, 2016
NCT05758831
NCT06586177
NCT05906992
NCT05755061
NCT01805336
NCT04940065
Lead Sponsor
Biogen
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions